- The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI)
- Ibezapolstat treatment of patients with CDI is associated with the restoration of beneficial bacterial classes in the gut
- Preparation continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection (CDI)
- Preparing to submit requests for regulatory guidance to initiate clinical trials in the European Union to be followed by the United Kingdom, Japan and Canada
- Ibezapolstat has previously received FDA QIDP and Fast-Track Designation from FDA
Acurx Pharmaceuticals Announced The Presentation Of A Scientific Poster At The Infectious Diseases Society Of America IDWeek 2024 Conference
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated